IFP Advisors’s Akero Therapeutics AKRO Stock Holding History

IFP Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-18	Closed	-$984	–	5021
2025 Q4	$984	Buy	18 +9	+100%	+$478	﹤0.01%	4074
2025 Q3	$427	Sell	9 -148	-94%	-$7.17K	﹤0.01%	4223
2025 Q2	$8.38K	Buy	157 +7	+5%	+$318	﹤0.01%	3025
2025 Q1	$6.07K	Buy	150 +149	+14,900%	+$6.32K	﹤0.01%	2755
2024 Q4	$28	Buy	+1	New	+$30	﹤0.01%	4395
2023 Q1	–	Sell	-2	Closed	-$1K	–	3383
2022 Q4	$1K	Hold	2	–	–	﹤0.01%	4274
2022 Q3	$1K	Buy	+2	New	+$31	﹤0.01%	4489

IFP Advisors's AKRO Position: Q1 2026 in Review

IFP Advisors sold out of Akero Therapeutics (AKRO) in Q1 2026, closing a stake of 18 shares — an estimated $984 sold.

IFP Advisors first reported a position in AKRO in Q3 2022 and held it in 7 quarters. The position peaked at $8.38K in Q2 2025. 0 funds tracked by Wall St. Rank hold AKRO as of Q1 2026.

IFP Advisors reported no remaining Akero Therapeutics position as of Q1 2026 after selling out during the quarter.
IFP Advisors sold 18 Akero Therapeutics shares in Q1 2026, an estimated $984.
IFP Advisors first reported a position in Akero Therapeutics in Q3 2022 and held it in 7 quarters.
IFP Advisors's Akero Therapeutics position peaked at $8.38K in Q2 2025.
0 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2026.

Based on IFP Advisors's 13F filing for Q1 2026, filed 13 Apr 2026.